Cargando…

Evaluating the natural growth rate of metastatic cancer to the brain

BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions bef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobets, Andrew J., Backus, Reid, Fluss, Rose, Lee, Alan, Lasala, Patrick A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533080/
https://www.ncbi.nlm.nih.gov/pubmed/33024592
http://dx.doi.org/10.25259/SNI_291_2020
_version_ 1783590060208160768
author Kobets, Andrew J.
Backus, Reid
Fluss, Rose
Lee, Alan
Lasala, Patrick A.
author_facet Kobets, Andrew J.
Backus, Reid
Fluss, Rose
Lee, Alan
Lasala, Patrick A.
author_sort Kobets, Andrew J.
collection PubMed
description BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions before the initiation of any CNS- directed therapy. METHODS: A total of 700 patients were screened, identifying 18 cancer patients (13 breast and 5 lung) with 29 brain metastases that were serially imaged from 2011 to 2017 before treatment for their intracranial metastases. Growth rates were measured by contouring lesions serially across at least two MRI studies in iPlan software by independent raters. These values were then compared between primary (breast and lung) cancer cohorts. RESULTS: The mean age at diagnosis was 53 and 95% were female. The interval between primary cancer diagnosis and brain metastases was 4.6 years and 1.2 years in the breast and lung cancer groups, respectively. Of the breast and lung cancer patients, 23% and 40% were deceased, with respective 5.08 cm(3) and 2.44 cm(3) initial tumor volumes. The average growth rate of lung and breast tumors was 0.018 and 0.040 cm(3)/day, respectively, with deceased patients having larger and faster growing tumors. Breast and lung metastases grew 2.39% and 1.14% of their total volumes daily and doubling times were 86 and 139 days, respectively. CONCLUSION: This investigation provides a unique perspective into the biological growth of metastatic brain lesions. It is our hope that this study guides timing of treatment and informs both clinicians and patients of tumor growth kinetics before initiating treatment for intracranial metastases.
format Online
Article
Text
id pubmed-7533080
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Scientific Scholar
record_format MEDLINE/PubMed
spelling pubmed-75330802020-10-05 Evaluating the natural growth rate of metastatic cancer to the brain Kobets, Andrew J. Backus, Reid Fluss, Rose Lee, Alan Lasala, Patrick A. Surg Neurol Int Original Article BACKGROUND: Brain metastases are becoming increasingly more prevalent as cancer patients survive longer with both improved local and systemic therapy. Little is known, however, of the natural growth rates of brain metastases. This investigation aims to ascertain this growth rate of these lesions before the initiation of any CNS- directed therapy. METHODS: A total of 700 patients were screened, identifying 18 cancer patients (13 breast and 5 lung) with 29 brain metastases that were serially imaged from 2011 to 2017 before treatment for their intracranial metastases. Growth rates were measured by contouring lesions serially across at least two MRI studies in iPlan software by independent raters. These values were then compared between primary (breast and lung) cancer cohorts. RESULTS: The mean age at diagnosis was 53 and 95% were female. The interval between primary cancer diagnosis and brain metastases was 4.6 years and 1.2 years in the breast and lung cancer groups, respectively. Of the breast and lung cancer patients, 23% and 40% were deceased, with respective 5.08 cm(3) and 2.44 cm(3) initial tumor volumes. The average growth rate of lung and breast tumors was 0.018 and 0.040 cm(3)/day, respectively, with deceased patients having larger and faster growing tumors. Breast and lung metastases grew 2.39% and 1.14% of their total volumes daily and doubling times were 86 and 139 days, respectively. CONCLUSION: This investigation provides a unique perspective into the biological growth of metastatic brain lesions. It is our hope that this study guides timing of treatment and informs both clinicians and patients of tumor growth kinetics before initiating treatment for intracranial metastases. Scientific Scholar 2020-08-21 /pmc/articles/PMC7533080/ /pubmed/33024592 http://dx.doi.org/10.25259/SNI_291_2020 Text en Copyright: © 2020 Surgical Neurology International http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kobets, Andrew J.
Backus, Reid
Fluss, Rose
Lee, Alan
Lasala, Patrick A.
Evaluating the natural growth rate of metastatic cancer to the brain
title Evaluating the natural growth rate of metastatic cancer to the brain
title_full Evaluating the natural growth rate of metastatic cancer to the brain
title_fullStr Evaluating the natural growth rate of metastatic cancer to the brain
title_full_unstemmed Evaluating the natural growth rate of metastatic cancer to the brain
title_short Evaluating the natural growth rate of metastatic cancer to the brain
title_sort evaluating the natural growth rate of metastatic cancer to the brain
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533080/
https://www.ncbi.nlm.nih.gov/pubmed/33024592
http://dx.doi.org/10.25259/SNI_291_2020
work_keys_str_mv AT kobetsandrewj evaluatingthenaturalgrowthrateofmetastaticcancertothebrain
AT backusreid evaluatingthenaturalgrowthrateofmetastaticcancertothebrain
AT flussrose evaluatingthenaturalgrowthrateofmetastaticcancertothebrain
AT leealan evaluatingthenaturalgrowthrateofmetastaticcancertothebrain
AT lasalapatricka evaluatingthenaturalgrowthrateofmetastaticcancertothebrain